Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03485547
Recruitment Status : Recruiting
First Posted : April 2, 2018
Last Update Posted : October 15, 2018
Sponsor:
Collaborator:
AbbVie
Information provided by (Responsible Party):
Andrew Lane, Dana-Farber Cancer Institute

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : April 30, 2021
  Estimated Study Completion Date : April 30, 2025